HER2 Dimerization Detection for Lung Cancer Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating lung cancer with HER2-targeted therapies are ineffective due to reliance on HER2 protein expression, which is rare in lung tumors, leading to low response rates and lack of approved targeted therapies for HER2 mutant lung cancers.
Innovation Solution
Detecting elevated levels of HER2 dimerization in lung cancer patients using techniques like FRET, FLIM-FRET, and Western blotting to identify patients for treatment with HER2-targeted therapeutic agents, such as antibody-drug conjugates like ado-trastuzumab emtansine, independent of HER2 protein overexpression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HER2 protein expression is used to select patients for HER2-targeted therapy, then treatment can be administered, but response rates are low because HER2 protein overexpression is rare in lung tumors
Solution Approach 1:
The patent changes the selection parameter from HER2 protein expression level to HER2 dimerization activity. This parameter change allows identification of patients with HER2 mutant lung cancers who have elevated dimerization levels, expanding the patient population beyond those with protein overexpression while maintaining reliable response to HER2-targeted therapy.
Solution Approach 2:
The patent replaces the conventional IHC-based protein detection method with functional assays that measure HER2 dimerization activity. This substitution enables detection of HER2 mutant cancers through their functional activity (dimerization) rather than protein quantity, thereby identifying patients who would respond to therapy regardless of protein overexpression status.
2Ease of operation
If HER2 protein expression by IHC is used to identify patients, then patient selection is simple, but the method is ineffective because it does not detect HER2 mutant cancers with normal protein levels
Solution Approach 1:
The patent changes the detection parameter from static protein expression to dynamic dimerization activity. This allows identification of HER2 mutant cancers through their functional behavior rather than protein abundance, maintaining operational simplicity while dramatically improving treatment selection effectiveness.
3Adaptability or versatility
If HER2-targeted therapies are developed based on protein overexpression, then treatment can be administered, but no approved targeted therapy exists for HER2 mutant lung cancers due to low response rates
Solution Approach 1:
The patent changes the therapeutic indication parameter from protein overexpression to dimerization activity. This enables adaptation of HER2-targeted therapies to HER2 mutant lung cancers regardless of protein levels, expanding therapeutic applicability while ensuring reliable responses through functional activity-based selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach demonstrates increased responsiveness to HER2 antibody-drug conjugates in patients with elevated HER2 dimerization, achieving partial responses and prolonged disease control, highlighting HER2 mutation as a separate therapeutic target from amplification.
Implementation Method 1
HER2 dimerization levels are detected via fluorescence resonance energy transfer (FRET)
Implementation Method 2
fluorescence lifetime imaging microscopy-fluorescence resonance energy transfer (FLIM-FRET)
Data Source
AI summary
The present disclosure provides methods for determining whether a patient diagnosed with lung cancer will benefit from or is predicted to be responsive to treatment with a therapeutic agent that targets HER2. These methods are based on detecting elevated levels of HER2 dimerization in a biological sample obtained from a lung cancer patient. Kits for use in practicing the methods are also provided.